EDAP TMS S.A. to Present at Roth Capital Conference in New YorkLyon, France, August 24, 2006 - EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, announced management will present at the Roth Capital Partners New York Conference on September 6, 2006 at the Westin Time Square Hotel in New York, NY. The company roster will include a scheduled presentation at 4:00 p.m. Management will also be available to conduct individual meetings at the conference and in the Midtown New York area.

Institutional investors interested in meeting with management should contact Roth Capital Partners regarding conference meetings or Halliburton Investor Relations (Matt Kreps, 972-458-8000) for meetings outside the conference schedule. Information regarding the conference can be found online at www.rothconference.com .  The Roth Conference is available by invitation of Roth Capital Partners only.

EDAP TMS S.A. provides the Ablatherm-HIFU medical device for the treatment of localized prostate cancer by High Intensity Focused Ultrasound. Ablatherm-HIFU is widely regarded as the most advanced and clinically proven HIFU device for prostate cancer. HIFU therapy is fully approved in Europe, Canada, Australia and other regions as a noninvasive therapeutic choice offering patients a high rate of success with low side effects. The treatment is also proven effective with low side effects for patients suffering a recurrence of localized prostate cancer after prior radiation therapy.

Ablatherm-HIFU therapy is reimbursed in certain markets and the company continues to seek additional reimbursements. EDAP is presently increasing its marketing activity in conjunction with its approval for use in key European markets and a growing clinical interest from the urology community based on published and peer reviewed studies supporting Ablatherm-HIFU as an effective and attractive therapeutic choice for nonsurgical patients. Clinical studies are being conducted in the United States using Ablatherm-HIFU through EDAP's US partner HealthTronics.

Information about EDAP and HIFU therapy can be found online at www.edap-tms.com and www.hifu-planet.com .

About EDAP TMS S.A.
EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Halliburton Investor Relations at (972) 458-8000, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com.

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.